Claritas Rx Flags Data Deluge as Key Challenge for Rare Disease Manufacturers in 2026
Event summary
- Claritas Rx released a white paper on February 11, 2026, outlining five major trends shaping the specialty and rare disease market.
- The 'data deluge' from expanding data providers is highlighted as a significant trend requiring strategic adaptation.
- Hillary Gretton, Director of Data Strategy at Claritas Rx, emphasizes the need for real-time analytics and scenario planning.
- Claritas Rx will discuss these trends at the Rare Disease Summit on March 17th.
The big picture
Claritas Rx's white paper underscores the increasing complexity in the specialty and rare disease markets, driven by economic volatility, regulatory changes, and a surge in data providers. The company argues that traditional planning models are becoming obsolete, necessitating real-time analytics and AI-driven insights to maintain competitive edge and patient access.
What we're watching
- Data Strategy
- How the growing 'data deluge' will impact manufacturers' ability to forecast and plan effectively.
- Market Adaptation
- Whether manufacturers can build strategic agility amid economic, regulatory, and market access complexity.
- AI Integration
- The pace at which AI and machine learning will be adopted to benchmark performance and predict demand accurately.
Related topics